Cardiovascular success for Brilinta in Phase III study

25 February 2019
astrazeneca-large

London-listed AstraZeneca (LSE: AZN) has announced positive results from the Phase III THEMIS trial, which met its primary endpoint.

The results show that Brilinta (ticagrelor) plus aspirin delivered a statistically-significant reduction in a composite of major adverse cardiovascular events (MACE), compared to aspirin alone.

The data build on previous efforts AstraZeneca has made to show the cardiovascular benefits of Brilinta. Last year, results from a large real-world study suggested that the same combination could compare favorably with clopidogrel plus aspirin.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical